Atossa Therapeutics, Inc.
ATOS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $107 | $87 | $120 |
| - Cash | $52 | $58 | $65 | $71 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $49 | $22 | $48 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | $0 | $0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$9 | -$9 | -$7 | -$7 |
| % Margin | – | – | – | – |
| Net Income | -$9 | -$8 | -$7 | -$6 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.07 | -0.065 | -0.052 | -0.05 |
| % Growth | -7.4% | -25.4% | -3.8% | – |
| Operating Cash Flow | -$6 | -$7 | -$6 | -$7 |
| Capital Expenditures | -$0 | $0 | -$0 | $0 |
| Free Cash Flow | -$6 | -$7 | -$6 | -$7 |